Tart Cherries (Montmorency)

Food · §359

A glass of tart cherry juice an hour before bed buys the average older adult with insomnia about 84 extra minutes of sleep on the lab's polysomnograph Pigeon 2010; a marathon runner who pre-loads for five days recovers strength visibly faster than the placebo group Howatson 2010. The mechanism is a small dose of dietary melatonin riding on a polyphenol matrix that also dampens the inflammation a hard workout (or a creaky knee) generates. The catch is the sugar — 30 grams in an 8-oz glass, roughly a Coca-Cola — and the one claim it can't carry, which is the one most often made for it: it does not lower uric acid in actual gout patients when properly tested.

Do · Daily Evidence Emerging Chapter Food

The strongest two effects are sleep and exercise recovery — both modest, both real, both well-replicated. Inflammation markers come down with chronic use; the gout claim that the bottle's label often leans on does not survive the best trial of it. A daily habit, cheap in concentrate form, with no downside beyond the sugar load and a mild laxative effect at higher juice volumes.

Tart cherries — almost always the Montmorency cultivar in the studies and on the supermarket shelf — are dense in three things that matter: anthocyanins (the deep red pigment that doubles as an anti-inflammatory), a tiny but unusually well-absorbed dose of melatonin (the same chemical the brain releases at night to wind you down), and a broader pool of polyphenols that nudge the body's stress response. A 60 mL shot of concentrate delivers roughly 85 micrograms of melatonin — orders of magnitude less than a sleep tablet, but enough that you can measure the metabolite in the morning's urine the next day Howatson 2012.

The interesting bit is what else cherries do to the sleep pathway. The body makes its own melatonin out of tryptophan (the amino acid people associate with turkey), and the speed of that conversion depends on how much tryptophan is still floating around versus being diverted into a different chemical path. Cherry procyanidins slow that diversion down, leaving more tryptophan available — measured directly in the Pigeon mechanism study, where the ratio of breakdown products to intact tryptophan dropped after two weeks of nightly juice Pigeon 2010. So the melatonin in the fruit and the melatonin your own body makes are both being nudged up at once.

The anti-inflammation work runs on the anthocyanins. Cyanidin pigments dampen the same cellular switch (NF-κB) that flips on after a hard workout, an infection, or a flare-up of arthritis — the same mechanism behind every "eat the rainbow" recommendation, just delivered in an unusually concentrated form Bell et al. 2014.

What it actually does

Three effect clusters have replicated trial backing — sleep, exercise recovery, and chronic inflammation markers — and one famous claim does not. Take them in order.

Sleep: 20 to 85 extra minutes

The cleanest sleep study put eight older adults with chronic insomnia through two weeks of nightly tart cherry juice in a crossover design, with a sleep lab measuring what happened. They slept 84 minutes longer on the juice than on the placebo, and spent less time awake in the middle of the night Pigeon 2010. A second trial in healthier adults using a smaller concentrate dose found a smaller but consistent bump — more time in bed, better sleep efficiency, and you could literally measure the extra melatonin coming out the next morning Howatson 2012.

The honest read: somewhere between twenty minutes and an hour and a half of extra sleep, depending on how poorly you were sleeping to start. The worse the baseline, the bigger the move. A young adult who already gets seven solid hours will notice less; a sixty-year-old who's been waking up at 4 a.m. for a decade may notice a lot.

Exercise recovery: the strongest signal in the file

This is where the evidence is densest. The setup most studies use: load up for four or five days before a hard bout, drink through the day of, continue for two or three days after. The Howatson marathon trial measured strength, soreness, and a fistful of blood markers in twenty runners; the cherry group recovered their leg strength faster, hurt less, and showed lower inflammation on every marker checked Howatson 2010.

The translation: if you've signed up for a marathon, picked up an unaccustomed training block, or you're a weekend lifter who hates that the Tuesday workout still hurts from Saturday — pre-loading cherry is a cheap, well-evidenced lever. If you're doing comfortable, well-recovered training, you won't notice anything.

Inflammation markers: real but uneven

Twelve weeks of daily juice in older adults reliably drops C-reactive protein — the standard blood marker for low-grade inflammation that creeps up with age and that nobody quite knows what to do about Chai et al. 2019. The same effect shows up in the marathon trial as a smaller acute spike after the race Howatson 2010. But when researchers tried to translate that marker improvement into something a person actually feels — knee pain in mild-to-moderate osteoarthritis — the cherry group's pain dropped, and so did the placebo group's; cherry beat baseline but not the placebo Schumacher et al. 2013. So: the number on the lab sheet moves; the felt experience doesn't always follow.

Gout: the claim the bottle leans on, and the trial that broke it

This is the one to be careful about. There is real evidence that cherries lower uric acid acutely — ten healthy women given a couple of cups of cherries showed their urate drop measurably within five hours Jacob et al. 2003. And a one-year observational study of 633 gout patients found that cherry-eating days were followed by 35% fewer flares; if the patient was also on allopurinol, the protection rose to 75% Zhang et al. 2012. Those two studies are why every tart cherry bottle has "for gout" written on it somewhere.

The honest synthesis: the acute uric-acid drop is real, the observational flare protection is real, but the chronic urate lowering that would actually treat gout did not survive a proper test. Cherry is a reasonable add-on for someone already on allopurinol or febuxostat. It is not a substitute for them, and no rheumatology guideline recommends it as one.

How to take it

Almost every positive trial used one of two doses, and the doses are equivalent — the concentrate is just the juice with the water removed. Pick whichever fits your kitchen and budget.

The concentrate is dramatically cheaper per dose — a $20 bottle lasts a month — and the diluted shot is easier on the stomach and the blood sugar than the full glass of juice. The trade-off is taste; cherry concentrate is sharply sour and most people cut it with sparkling water and ice. The ready-to-drink juice tastes better but costs five to ten times as much for the same active dose.

Capsules and standardised extracts (around 500 mg/day of cherry powder) exist and have a small but positive trial base, including the recent inflammation work. Useful when travel or sugar makes juice impractical — but most of the evidence is in juice form, and the matrix of melatonin plus polyphenols plus procyanidins may matter in ways a powder doesn't replicate.

Catches and when not to

The other catch is the gut. Cherries (and all stone fruits) contain sorbitol, a natural sugar alcohol that pulls water into the intestine. At a glass-of-juice volume, some people get loose stools, gas, and bloating; people with irritable bowel syndrome often get more. Concentrate at the small shot dose is much less likely to do this.

Advanced kidney disease is the third one — concentrated juice carries a meaningful potassium load, and if your kidneys can't clear potassium normally, that matters. Clear it with your nephrologist.

Otherwise: this is a fruit. The safety profile is a fruit's safety profile.

What gets oversold

"It treats gout." The acute postprandial uric-acid drop is real, the observational flare association is real, but the only dose-ranging randomised trial in actual gout patients found no effect on serum urate at any dose, over 28 days, with or without allopurinol Stamp et al. 2020. Cherry is reasonable as an adjunct on top of standard medication; it is not a substitute for it, and the rheumatology field does not treat it as one.
"It's a melatonin alternative." A serving delivers around 85 micrograms of melatonin; an over-the-counter sleep tablet is 1,000 to 10,000 micrograms. If you're already taking a melatonin pill, cherry isn't a stronger version of it. The cherry effect is partly dietary melatonin, partly the tryptophan-pathway nudge from procyanidins, and partly the broader sleep-helpful polyphenol mix — a different intervention, not a more natural same one.
"It's a healthy energy drink." Eight ounces of juice is roughly thirty grams of sugar — the same as a soda. The win is the bioactive content, not the substrate.
"Capsules work the same." Capsules have a positive trial base and are convenient, but most of the evidence is for juice or concentrate, and we don't know whether the food matrix is doing some of the work. Default to liquid where you can.

What you'd notice

Be calibrated. Cherry is a small lever, not a transformation — and the small levers compound.

First week or two. If you're using it for sleep and you sleep badly to begin with, you'll wake up a little earlier feeling like you actually got enough — twenty to forty minutes of difference, somewhere in there, more if your baseline was bad. If you've been sleeping well already, you may not notice anything at all; the trials with healthy young adults showed smaller effects than the trials with older insomniacs. If you're using it for a hard training block, the Monday workout after a heavy Saturday hurts less than you expected — that's the soreness signal, and it shows up reliably enough that the meta-analysis catches it across fourteen separate studies.

First three months. For someone with chronic low-grade inflammation — the kind that doesn't have a name but shows up as a creeping CRP on your annual labs — the number moves down. Not to zero. Down a notch. Whether you notice that as anything other than a number is honestly mixed; the osteoarthritis trial found that knee pain dropped on cherry, but it also dropped on placebo, by roughly the same amount.

First year. The sleep effect compounded across 365 nights is the equivalent of roughly an extra week of nights. You probably won't experience it as "the cherry juice"; you'll experience it as having gradually become someone who sleeps reasonably well. The recovery effect compounded across a season of consistent training is the slightly higher volume you got away with because the worst recovery days were less catastrophic.

The frame to hold: this is a useful nutritional tool, similar in register to taking creatine for training or omega-3 for cardiovascular maintenance. It is not the lever that makes or breaks anything. It is a small lever that's cheap to pull.

A few adjacent threads worth knowing about. Tart cherry has small but real positive trials in two more domains that didn't make this entry's four headlines: a one-trial blood pressure signal in early-hypertensive men (about a 7% systolic drop from a single concentrate shot, Keane et al. 2016) and a single sustained-attention / mental-fatigue trial in middle-aged adults over three months Kimble et al. 2022. Single trials, treat as preliminary.

The closest neighbours in this catalogue are anything else that runs on the same anthocyanin and polyphenol machinery — blueberries, pomegranate, dark berries broadly — which produce overlapping effects via the same mechanism. For sleep specifically, the better-evidenced levers are sleep hygiene, light exposure timing, and (for diagnosed insomnia) cognitive-behavioural therapy for insomnia; cherry is a small add-on, not a substitute. For exercise recovery, the bigger levers are sleep, protein intake, and training periodisation; cherry is an icing-on-the-cake nutritional tool for the harder sessions.

Substance and claimed effects

Tart cherries (Prunus cerasus; chiefly the Montmorency cultivar in research and US commerce, Balaton secondarily) are a deeply pigmented stone fruit consumed as whole fruit, juice (reconstituted from concentrate at roughly 100 cherries per 8 oz glass), juice concentrate (typically 30–60 mL once or twice daily), or freeze-dried powder / extract capsules. The bioactive load that drives every claim below is the anthocyanin fraction (especially cyanidin-3-glucosylrutinoside, 26–40 mg per 100 g whole fruit), a small but unusually well-absorbed dose of dietary melatonin (2.1–13.5 ng/g fresh fruit, ~85 µg in a typical 60 mL concentrate dose), and a broader polyphenol pool (procyanidins, flavonols, hydroxycinnamic acids) Burkhardt et al. 2001. The four claimed effect clusters this entry covers are: sleep onset / duration (melatonin and tryptophan-pathway mediated), exercise-induced muscle soreness and recovery (anti-inflammatory / antioxidant), uric acid lowering and gout flare risk, and inflammatory marker reduction (CRP, IL-6, oxidative stress). Knock-on consequences with weaker but real trial backing — blood pressure, sustained attention / mental fatigue, osteoarthritis pain — are surfaced in research but treated as secondary; this entry does not cover the bone-resorption or ulcerative-colitis literature in depth.

Evidence by addressing question

mechanism

Three converging mechanisms carry the entire benefit profile, each independently evidenced. Melatonin delivery: tart cherries contain endogenous melatonin at 2.1–13.5 ng/g, quantified by HPLC in Montmorency and Balaton cultivars Burkhardt et al. 2001. A 60 mL concentrate serving delivers roughly 85 µg melatonin — orders of magnitude below pharmacological tablets (1–10 mg) but enough to measurably raise urinary 6-sulfatoxymelatonin output (a validated melatonin metabolite marker) Howatson et al. 2012. Tryptophan availability and IDO inhibition: cherry procyanidins (notably procyanidin B-2) inhibit indoleamine 2,3-dioxygenase in vitro, reducing tryptophan degradation along the kynurenine pathway and increasing tryptophan substrate available for serotonin and melatonin synthesis; the Pigeon mechanism trial showed a serum kynurenine-to-tryptophan ratio decrease after cherry juice Pigeon et al. 2010. Anthocyanin anti-inflammatory action: cyanidin glycosides suppress NF-κB-driven cytokine production (IL-6, TNF-α) and inhibit cyclooxygenase-1/2 in vitro at concentrations achievable from dietary intake, plausibly explaining both the urate and CRP effects and the dampening of exercise-induced inflammation Bell et al. 2014. The anthocyanin mechanism is the same one that underlies blueberry, elderberry, and pomegranate effects — tart cherry is unusual in its density, not its category.

evidence

Sleep. Two small but methodologically clean RCTs anchor the sleep claim. The Pigeon pilot in 15 older adults with chronic insomnia (8 completers, randomised double-blind crossover, 240 mL tart cherry juice twice daily for 2 weeks) showed an 84-minute increase in total sleep time on polysomnography and significant reductions in wake-after-sleep-onset versus placebo Pigeon et al. 2010. The Howatson 2012 trial in 20 healthy adults (60 mL concentrate twice daily, 7 days) found increased sleep time, sleep efficiency, and time in bed alongside elevated urinary melatonin output — the mechanism hookup is explicit Howatson et al. 2012. A 2023 systematic review of 8 trials concluded the effect on sleep duration is consistent (~25–85 minutes) but modest; effects on sleep latency and PSQI scores are mixed.

Exercise recovery. The strongest evidence cluster. Howatson 2010 randomised 20 marathon runners to cherry juice or placebo (5 days pre, day of, 2 days post): isometric strength recovered significantly faster, CRP and IL-6 were attenuated, and serum uric acid rose less Howatson et al. 2010. Kuehl 2010 (54 long-distance runners, 7 days of cherry juice) reported significantly less pain progression during the race in the cherry arm Kuehl et al. 2010. The 2021 Hillman meta-analysis of 14 trials found small-to-moderate beneficial effect sizes for muscle soreness (SMD ~-0.44), strength recovery (SMD ~-0.61), and power (SMD ~-0.57); inflammatory biomarkers IL-6 and IL-8 also reduced Hillman & Uhranowsky 2021. Effects are largest for high-eccentric / endurance protocols (marathons, downhill running) and weakest for short, low-damage bouts.

Uric acid and gout. Mechanism evidence from Jacob 2003: 10 healthy women given 280 g Bing sweet cherries (note: not tart; same anthocyanin class) showed plasma urate drop from 214 to 183 µmol/L at 5 hours postdose with corresponding urinary urate excretion increase, plus a trend toward CRP reduction Jacob et al. 2003. The Zhang 2012 case-crossover of 633 gout patients tracked over 1 year found a 35% lower risk of flares in 2-day windows after cherry consumption (any form), 75% lower when combined with allopurinol; the protective association persisted after adjustment for sex, BMI, purine intake, alcohol, diuretics and anti-gout medication Zhang et al. 2012. But the highest-quality RCT — Stamp 2020, 50 gout patients across 5 dose arms (placebo to 30 mL twice daily) for 28 days — found no dose-response effect on serum urate, urine urate excretion, urinary anthocyanins, or flare frequency Stamp et al. 2020. The honest read: the acute postprandial urate dip is real (Jacob), the flare-association signal is real but observational and not flare-prevention proof (Zhang), and the chronic serum-urate-lowering effect that would matter for sustained gout control did not survive a proper RCT (Stamp).

Inflammation. Cleanest single trial: Chai 2019 in 37 older adults, 480 mL tart cherry juice daily for 12 weeks, significantly reduced CRP, malondialdehyde, and oxidised LDL versus placebo; TNF-α unchanged Chai et al. 2019. The Howatson 2010 marathon trial showed acute CRP and IL-6 attenuation in an exercise-stress model Howatson et al. 2010. The OA-knee Schumacher 2013 trial (58 patients, 16 oz/day for 6 weeks, crossover) showed an hsCRP drop but failed to beat placebo on the primary pain endpoint (WOMAC) Schumacher et al. 2013. A 2023 meta-analysis of 21 trials found a moderate-certainty CRP reduction in pooled analysis but no effect on hsCRP in the higher-quality subgroup — the inflammation signal exists but isn't uniformly robust.

protocol

Dosing across positive trials clusters tightly: 240 mL ready-to-drink juice twice daily (Pigeon insomnia, Howatson marathon, Chai inflammation, Schumacher OA — the most-replicated dose) or 30 mL concentrate diluted in water, twice daily (Howatson sleep, Keane blood pressure — concentrate equivalent). For exercise recovery: load for 4–5 days before the strenuous bout, continue through the day of and for 2–3 days after — pre-loading is what the marathon protocols used and the effect tracks the loading window. For sleep: 1–2 hours before bed; chronic 1–2 weeks of nightly use rather than single doses. For inflammation / gout-flare risk: chronic daily use, weeks to months. Cherry capsules / extracts (~500 mg standardised to anthocyanin content) appear in several trials including the recent CRP study but the juice-format trials are denser and the bioactive matrix may matter; capsules are reasonable when juice is impractical (travel, sugar load, cost).

contraindications

Diabetes / glycaemic control is the headline concern: 8 oz tart cherry juice carries 25–33 g sugar, roughly the same as Coca-Cola; concentrate diluted is somewhat lower. Diabetics or pre-diabetics should use concentrate (small volume) or extract capsules. Sorbitol content (a polyol naturally present in stone fruits) commonly causes loose stools, bloating, and gas at higher juice volumes; IBS sufferers report flares. Anti-platelet effects of dietary anthocyanins are theoretically additive with warfarin and other anticoagulants — no documented bleeding events from cherry but the interaction is plausible and not formally tested. Concentrated juice carries significant potassium (~500 mg/8 oz); advanced kidney disease patients should clear with a clinician. Otherwise tart cherry is a food and has the safety profile of a food.

misconceptions

"Tart cherry juice treats gout." The observational and acute-mechanism evidence is real, but the dose-ranging RCT explicitly designed to test it found no chronic urate-lowering effect Stamp et al. 2020. Cherry juice is reasonable as an adjunct for someone already on allopurinol or febuxostat (the Zhang signal is strongest with combined therapy), not as a substitute. "Tart cherry's melatonin content explains the sleep effect." The melatonin dose in a serving (~85 µg) is roughly 1/10 to 1/100 of a sleep tablet; the tryptophan-availability mechanism is probably doing as much or more of the work Pigeon et al. 2010. "Cherry juice is a healthier energy drink." 8 oz of juice is ~30 g sugar — caloric load matches soda; the win is the bioactives, not the substrate. "Capsules are equivalent." Most trials are juice-format; the anthocyanin–polyphenol–melatonin matrix may need the food vehicle to work. Capsule trials exist and are positive, but the evidence is denser for juice.

practicalities

Cost: ready-to-drink juice runs $1.50–$3 per 8 oz serving; daily dosing is roughly $50–$200/month. Concentrate is dramatically cheaper per serving — a 16 oz bottle ($15–$25) yields a month of 30 mL doses. Capsules / extract bottles run $15–$30 for a month. Availability: any US supermarket carries one Montmorency brand (Cheribundi, R.W. Knudsen, Lakewood, Tart is Smart); the concentrate format and capsules are easier online. The juice tastes assertively sour; cutting concentrate with sparkling water and ice makes daily dosing bearable.

population variability

Effects are most pronounced in: older adults (sleep — Pigeon and Howatson), runners and field-sport athletes after heavy eccentric work (recovery — multiple trials), and individuals with baseline inflammation (Chai, Schumacher CRP signal). Less compelling in: short-duration low-damage exercise, healthy young adults without inflammatory baseline, gout patients seeking monotherapy (Stamp negative).

stakes / payoff

The honest payoff for the typical reader is modest and measurable: 20–85 minutes more sleep (in trials), measurably faster strength return after a hard workout, lower CRP at 12 weeks. Not transformative, but accumulating — sleep effect alone over a year of nightly use is the equivalent of an extra week of nights. The stakes of not using it are zero (it is a fruit, not a missed intervention); the right frame is "useful nutritional lever for sleep and recovery", not "must-do health practice".

out-of-scope

Sweet cherries (Bing, Rainier) overlap mechanistically — Jacob 2003 used Bing — but tart cherries are denser in anthocyanins and melatonin; the trial evidence here is overwhelmingly tart-specific. The bone resorption literature (postmenopausal women, single small trial), the ulcerative colitis pilot, and the blood pressure work (Keane 2016, real ~7% SBP reduction in early-hypertensive men) are notable but not the four headlining clusters; the article surfaces them briefly. Cognitive performance (Kimble 2022 — sustained attention improved at 3 months in middle-aged adults) is genuine but a single trial.

Credibility range

Optimist case

The mechanism stack is unusually well-mapped — melatonin delivery measurable in urine, tryptophan IDO inhibition demonstrated in vitro with serum confirmation, NF-κB and COX inhibition consistent with the broader anthocyanin literature. The clinical evidence is small-sample but multi-replicated across three independent domains (sleep, recovery, inflammation), with effect sizes consistent across labs and largely in the same direction. The Howatson marathon trial is a single intervention showing simultaneous reduction in muscle damage markers, inflammation, and oxidative stress — that kind of multi-axis coherence is hard to fake. As a food with thousands of years of human consumption history and zero serious safety signal, the asymmetry is favourable: small upside per dollar, near-zero downside.

Skeptic case

Sample sizes are tiny — Pigeon 2010 had 8 completers, Howatson 2012 had 20, Keane 2016 had 15 — and almost every positive trial has been conducted by labs with declared funding from the Cherry Marketing Institute or cherry-industry sponsors. Publication bias in industry-sponsored nutraceutical literature is well-documented. The single highest-quality dose-ranging RCT in the field (Stamp 2020, 5 arms, 50 patients) found no gout urate effect at any dose. The sustained-attention finding (Kimble 2022) is a single trial. CRP changes are typically small and inconsistent across the meta-analysis subgroups. The melatonin "dose" in a serving is microgram-scale — orders of magnitude below validated melatonin pharmacology. Most positive sleep results disappear when standardised PSG endpoints are required instead of self-reported PSQI.

Author's call

Genuinely useful but oversold. The sleep signal is small but mechanistically plausible and replicated — worth trying if sleep is the bottleneck, with realistic expectations (~20–30 minutes most adults, more in older insomniacs). The exercise-recovery signal is the strongest and most reproducible — clearly worth the pre-load before a marathon, a high-volume training block, or unaccustomed eccentric work. The gout claim is the weakest — observational signal real, RCT negative for chronic urate; useful as adjunct, useless as monotherapy. The inflammation effect is real at the marker level (CRP) but doesn't reliably translate to clinical endpoints (Schumacher OA pain). Evidence rating settles at 3 — multiple replicated positive trials, mechanism solid, but industry-funded skew and the Stamp negative keep it from 4. Controversy at 2 — sub-field disagreement on gout chronicity, otherwise fairly aligned.

Stakeholder and incentive map

Cherry Marketing Institute / Montmorency growers. A national industry body that explicitly funds the majority of clinical research on tart cherry. Most positive trials disclose this. Not a disqualifier — the studies are real and externally publishable — but a reason for second-pass skepticism on any single positive finding.
Sports nutrition / supplement industry. Tart cherry capsules and standardised extracts (Cherry PURE, CherryActive, etc.) are a profitable category in the post-workout supplement space; product-claim hyperbole common.
Rheumatology guideline bodies (ACR, EULAR). Neutral-to-skeptical. The 2020 ACR gout guideline does not recommend cherry juice as therapy. Stamp 2020 (NZ rheumatologist, no industry funding) is the field's preferred trial.
Sleep medicine (AASM). No formal position; melatonin generally is recognised as a circadian agent more than a hypnotic.
Independent academic labs. Howatson (Northumbria) is the most-cited; not industry-funded directly but a frequent collaborator. Chai (Florida State), Keane, and the Kuehl Oregon group are credible.

Population variability

Best responders: older adults with insomnia (Pigeon, Howatson 2012 cohort), endurance athletes during high-eccentric / high-volume training blocks (Howatson 2010, Kuehl, multiple meta-analysed trials), adults with elevated baseline CRP (Chai). Weakest responders: gout patients seeking monotherapy (Stamp negative), healthy young adults without an inflammatory stressor (Schumacher mixed), short-duration moderate-intensity exercise. The blood pressure effect (Keane 2016) was in early-hypertensive men; whether it extends to normotensive adults is unclear.

Knowledge gaps

No large multicentre RCT in any indication — every positive trial is sub-100 participants. No head-to-head against melatonin tablets for sleep, against allopurinol for gout, against NSAIDs for recovery. No long-term (year-plus) safety data on daily concentrated dosing in diabetics or kidney-impaired populations. The bioactive responsible for each effect remains under-attributed — melatonin, anthocyanins, procyanidins, or a synergy — meaning standardised extract formulations may or may not match juice. The negative Stamp gout trial deserves replication; if confirmed, the gout claim should be fully retracted from the field's recommendations.

Scope vs brief. The brief named four consequence clusters — sleep, exercise recovery, uric acid / gout, inflammation — and the entry covers all four end to end, with the gout one explicitly debunked in evidence and misconceptions per the Stamp 2020 negative trial. No silent narrowing.

Rating calls worth flagging.

evidence: 3 reflects the tension between many positive small trials and the single best-designed dose-ranging RCT being negative. A naive read of the meta-analyses would push to 4; the Stamp 2020 negative and the industry-funding skew across the field hold it at 3. Not 2 because the sleep and recovery signals are independently replicated by non-industry labs.
sleep: 3 not 4. Pigeon's +84 min PSG signal in 8 completers is the high-water mark; healthy-adult trials show smaller effects. "Meaningful, named effect" fits; "substantial sleep transformation" does not.
focus: 1 and energy: 1 are single-trial calls (Kimble 2022). Tempted by 0 but the dossier surfaces real if preliminary signal — went conservative-positive rather than zero.
longevity: 1 earned only via the indirect CRP / BP signal; no direct mortality data exists. Score it at 0 would be cleaner but the chronic-inflammation reduction is real and the catalogue treats that kind of indirect chain at 1.
cost_burden: 1 presumes concentrate-format usage; ready-to-drink juice at $50–200/month nudges toward 2. Flagged in the article body.

What was excluded and why.

Bone resorption (Dodier 2021, postmenopausal women) — single small trial, doesn't anchor a dimension above what's already scored.
Ulcerative colitis pilot (2024) — too preliminary, narrow population, would need its own entry if it replicates.
Sweet cherries (Bing, Rainier) — overlapping mechanism but the trial base is overwhelmingly Montmorency-specific; Jacob 2003 used Bing and is cited as supporting mechanism only.
Blood pressure (Keane 2016) and sustained attention (Kimble 2022) are mentioned in out-of-scope rather than given their own sections — single trials, secondary to the four headlining clusters.

Future links. Once they exist, this entry should cross-link to: blueberries, pomegranate, anthocyanin / polyphenol (overlapping mechanism), melatonin (supplemental) (the more direct sleep lever — the comparison is honest and useful), CBT-I and sleep hygiene (the bigger sleep levers cherry sits on top of), creatine and protein intake / training periodisation (the bigger recovery levers).

Separate-entry candidates. Dietary melatonin sources as a category piece (cherries, walnuts, eggs, milk — what dose, when it matters). Anthocyanins / dark-pigment polyphenols as a cross-substance mechanism entry.

Industry-funding caveat. Most positive trials disclose Cherry Marketing Institute or grower-association funding. Not a disqualifier — studies are externally publishable, mechanism is genuinely well-mapped, and the negative Stamp 2020 was independently funded — but a standing reason for second-pass skepticism. Surfaced in the credibility range, deliberately not in the article body (would feel like editorial axe-grinding without earning the space).